142 related articles for article (PubMed ID: 37932927)
1. A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome.
Liu H; Ding K; Zhang W; Xing L; Wang Y; Wang H; Song J; Li L; Fu R
Br J Haematol; 2024 Mar; 204(3):1082-1085. PubMed ID: 37932927
[TBL] [Abstract][Full Text] [Related]
2. [Outcomes of splenectomy in relapsed/refractory autoimmune hemolytic anemia].
Fan SB; Wang ZJ; Mao Q; Tong CF; Zhai WT; Zheng YZ; Sun CX; Shi J
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):132-136. PubMed ID: 30831628
[No Abstract] [Full Text] [Related]
3. Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study.
Zhang Z; Hu Q; Yang C; Chen M; Han B
Ann Med; 2023; 55(2):2282180. PubMed ID: 37967535
[TBL] [Abstract][Full Text] [Related]
4. Evans syndrome: a study of six cases with review of literature.
Dhingra KK; Jain D; Mandal S; Khurana N; Singh T; Gupta N
Hematology; 2008 Dec; 13(6):356-60. PubMed ID: 19055865
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune haemolytic anaemia.
Argüello Marina M; López Rubio M; Castilla García L
Med Clin (Barc); 2023 Jan; 160(1):30-38. PubMed ID: 36334945
[TBL] [Abstract][Full Text] [Related]
6. Maintenence rituximab following induction in autoimmune cytopenias.
Rai MP; Lee EJ; Bussel JB
Br J Haematol; 2023 Jul; 202(1):153-158. PubMed ID: 37086173
[TBL] [Abstract][Full Text] [Related]
7. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
8. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ; Zhou KS; Liu LH; Zhang MZ; Li ZM; Ji CY; Xu W; Liu T; Xu B; Wang X; Gao SJ; Zhang HL; Hu Y; Li Y; Cheng Y; Yang HY; Cao JN; Zhu ZM; Hu JD; Zhang W; Jing HM; Ding KY; Zhang XY; Zhao RB; Zhang B; Tian YM; Song YP; Song YQ; Zhu J
Blood Adv; 2023 Aug; 7(16):4349-4357. PubMed ID: 37078706
[TBL] [Abstract][Full Text] [Related]
9. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia.
Majer RV; Hyde RD
Clin Lab Haematol; 1988; 10(4):391-5. PubMed ID: 3250787
[TBL] [Abstract][Full Text] [Related]
10. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study.
Ducassou S; Leverger G; Fernandes H; Chambost H; Bertrand Y; Armari-Alla C; Nelken B; Monpoux F; Guitton C; Leblanc T; Fisher A; Lejars O; Jeziorski E; Fouissac F; Lutz P; Pasquet M; Pellier I; Piguet C; Vic P; Bayart S; Marie-Cardine A; Michel M; Perel Y; Aladjidi N
Br J Haematol; 2017 Jun; 177(5):751-758. PubMed ID: 28444729
[TBL] [Abstract][Full Text] [Related]
11. The potential of metabolomics as a predictive guide for clinical management in autoimmunity against red blood cells.
Kapur R
Br J Haematol; 2023 Apr; 201(1):13-14. PubMed ID: 36597858
[TBL] [Abstract][Full Text] [Related]
12. Management of Evans syndrome.
Norton A; Roberts I
Br J Haematol; 2006 Jan; 132(2):125-37. PubMed ID: 16398647
[TBL] [Abstract][Full Text] [Related]
13. Paediatric-onset Evans syndrome: Breaking away from refractory immune thrombocytopenia.
Aladjidi N; Pincez T; Rieux-Laucat F; Nugent D
Br J Haematol; 2023 Oct; 203(1):28-35. PubMed ID: 37735545
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic profile in patients with primary warm autoimmune haemolytic anaemia.
Rabelo IB; Chiba AK; Moritz E; D'Amora P; Silva IDCG; Rodrigues CA; Barros MMO; Bordin JO
Br J Haematol; 2023 Apr; 201(1):140-149. PubMed ID: 36484101
[TBL] [Abstract][Full Text] [Related]
15. Evans Syndrome and pregnancy: A case report with literature review.
Parveen S; Mukhtar R; Shafee S; Mehmood R
J Pak Med Assoc; 2019 Jul; 69(7):1047-1048. PubMed ID: 31983745
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
[TBL] [Abstract][Full Text] [Related]
17. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
Front Oncol; 2022; 12():901797. PubMed ID: 35785180
[TBL] [Abstract][Full Text] [Related]
18. Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib.
Li M; Liu L; Ding B; Song X; Xia A; Han Y; Song Y; Wei X; Zhou H
Br J Haematol; 2022 Dec; 199(5):e37-e42. PubMed ID: 36223900
[No Abstract] [Full Text] [Related]
19. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study.
Li H; Ji J; Du Y; Huang Y; Gu H; Chen M; Wu R; Han B
Exp Hematol; 2020 Sep; 89():87-95. PubMed ID: 32771553
[TBL] [Abstract][Full Text] [Related]
20. Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome.
Carli G; Visco C; Falisi E; Perbellini O; Novella E; Giaretta I; Ferrarini I; Sandini A; Alghisi A; Ambrosetti A; Rodeghiero F
Ann Hematol; 2016 May; 95(6):863-70. PubMed ID: 27001309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
